Sirona Biochem Corp V.SBM

TFC039 -hero or zero? Who knows-not even Howard apparently

[Pareto8020]

Remember this from the CEO update 6 months ago.....

TFC-039

Human Diabetes
Our partner, Wanbang Biopharmaceuticals, has informed us that our compound for type 2 diabetes (TFC-039) has completed their Phase I studies and the data is in the analysis phase. We expected to hear the results of this before the Chinese New Year in early February, however, they have experienced delays in the data analysis. We are now waiting and pushing to have a final report of these results and will update shareholders as soon as material information is available for release.

Or how about this tale from Q1....
 

TFC-039

TFC-039 for a type 2 diabetes pharmaceutical has completed another major phase in development and material information is pending.

TFC-039 for animal health continues to progress. We are in discussions with two international companies on this project and as such it has taken more time than expected to coordinate. Sirona and its consultants have structured and negotiated this unique partnership. We have closed binding terms on one side of this deal with the partner and we anticipate the other partner closing soon. Until such time that both partners have agreed to all terms, the details must remain confidential.

Seriously......WTF are they doing????

[Crazydan]

Seriously are you waiting for results!!!!!! You are more of an Idi$t that I thauht. When you have excuses once OK than two well maybe but on and on then it's a scam. Everything must remain confidential because he is lying!!! Howard is a devious man. Definition: showing a skillful use of underhanded tactics to achieve goals.

[DexterMorgan]

SBM is simply an ATM for Howie et.al.  He is milking it for all its worth.  I'll say it again, and again, and again.....this venture needs a new management team.  Period, end stop!  CEO and CFO are pulling off six figure incomes with stock perks while working only part time.  Total joke!  Yes, I am a shareholder and believe in the core platform technology and its